Benson R C, Gorman P A, O'Brien P C, Holicky E L, Veneziale C M
Cancer. 1987 May 1;59(9):1599-606. doi: 10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v.
The authors investigated the ability of androgen receptor binding in prostate cancer tissue to predict the response of prostate cancer patients to endocrine therapy. The clinical response of 37 previously untreated patients with various grades and stages of prostate cancer was correlated with androgen receptor binding and detailed histologic data obtained before treatment. All patients underwent cold-punch transurethral resection of the prostate and received endocrine therapy. The association between time to progression and cytosolic androgen binding was not significant. However, the associations of time to progression to nuclear binding and to total androgen binding were significant (P = 0.029 and 0.038, respectively). The authors found no association between clinical stage and time to progression, but did find an association between time to progression and pathologic grade (P = 0.003); grade 4 lesions were the least responsive to hormone therapy. When grade 4 lesions were excluded (N = 3), binding levels were still predictive of progression independently of grade and stage. The authors conclude that nuclear receptor binding activity in localized and metastatic prostate cancer tissue is predictive of response to hormonal manipulation.
作者研究了前列腺癌组织中雄激素受体结合能力，以预测前列腺癌患者对内分泌治疗的反应。37例先前未经治疗、患有不同分级和分期前列腺癌的患者的临床反应，与雄激素受体结合情况以及治疗前获得的详细组织学数据相关联。所有患者均接受了经尿道前列腺冷切术，并接受了内分泌治疗。进展时间与胞质雄激素结合之间的关联不显著。然而，进展时间与核结合以及总雄激素结合之间的关联显著（P分别为0.029和0.038）。作者发现临床分期与进展时间之间无关联，但确实发现进展时间与病理分级之间存在关联（P = 0.003）；4级病变对激素治疗的反应最差。当排除4级病变（N = 3）时，结合水平仍然独立于分级和分期预测进展情况。作者得出结论，局限性和转移性前列腺癌组织中的核受体结合活性可预测对激素操纵的反应。
